ARD Podcast

Six-week treatment with low-dose prednisolone in patients with painful hand osteoarthritis

This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone.

Highlights from ACR: guselkumab, ixekizumab and secukinumab in SpA

Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.

TULIP 2: Efficacy and Safety of Anifrolumab in Patients

TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.
In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.

TULIP 1 - highlights from the ACR meeting

TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.

Capture Hi-C reveals novel drug targets in rheumatic diseases

The paper discussed in this podcast provides an approach, using Capture Hi-C data, to link genetic associations to potential causal genes and assess the potential of drug repurposing in three rheumatic diseases. This has the potential to identify genes which are functionally relevant and the target of existing therapies, which could provide new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/8/1127.

EULAR recommendations for the management of systemic lupus erythematosus

The highlights of the latest update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence, are discussed in this podcast.
Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.

Musculoskeletal diseases on the rise worldwide and affecting developed countries the most

Musculoskeletal diseases have increased significantly between 2000 and 2015 and are now the second cause of years lived with disability worldwide, a study recently published by ARD concludes. The paper also adds that the burden is higher in Europe.
“The richest the country, the highest the burden of musculoskeletal diseases”, says the leading author. Professor Laurent Arnaud and Dr Eden Sebbag(Department of Rheumatology - Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, France) discuss the details of the study with ARD's Social Media Advisor, Dr Paul Studenic.
Read the full paper: https://ard.bmj.com/content/78/6/844.

Three tips to get your manuscript published by ARD

Find out how to increase your chances of a successful submission in this very short podcast with Annals of the Rheumatic Diseases’s Associate Editor Francis Berenbaum. He is interviewed by the Social Media Advisor of the journal, Christophe Richez.
Read more information for authors on the ARD website: https://ard.bmj.com/pages/authors/.
Submit your manuscript here: https://mc.manuscriptcentral.com/ard.

Early inflammatory arthritis outcomes: what changed in the new millennium?

A study that compares the 10-year outcome (disease activity, disability, mortality) of two cohorts of patients with inflammatory polyarthritis recruited 10 years apart is discussed in this podcast. The results from the UK’s Norfolk Arthritis Register are shared by two of its co-authors from the Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, School of Biological Sciences, Manchester Academic Health Science Centre: James Gwinnutt and Suzanne Verstappen (NIHR Manchester Biomedical Research Centre) in conversation with the social media advisor for ARD Meghna Jani.
Read the full paper on the Annals of the Rheumatic Diseases website: https://ard.bmj.com/content/77/6/848.

Similar performance of Humira and BI695501 biosimilar in active rheumatoid arthritis

The switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity in patients with moderately to severely active rheumatoid arthritis, according to a study recently published by ARD and discussed in this short podcast.
Professor Stanley Cohen (Metroplex Clinical Research Center, Dallas, Texas, USA) tells ARD’s social media advisor Elena Nikiphorou (clinical researcher at King’s College London, UK) how the conclusions should have an important economic impact, particularly in less favoured clinical settings in the world.
Read the full paper on the Annals of the Rheumatic Diseases website: http://dx.doi.org/10.1136/annrheumdis-2017-212245.